Development and validation of a liquid chromatography–mass spectrometric method for the determination of DPC 423, an antithrombotic agent, in rat and dog plasma

This publication has 26 references indexed in Scilit:

• Recent advances in Factor Xa inhibitors
  Expert Opinion on Therapeutic Patents, 2001
• Inhibitors of Factor Xa
  Expert Opinion on Therapeutic Patents, 2001
• Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa
  Journal of Medicinal Chemistry, 2001
• Isoxazolines and isoxazoles as factor Xa inhibitors
  Bioorganic & Medicinal Chemistry Letters, 2000
• Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers
  Clinical Pharmacology & Therapeutics, 1999
• Factor Xa inhibitors
  Expert Opinion on Therapeutic Patents, 1999
• Synthetic Inhibitors of Thrombin and Factor Xa: From Bench to Bedside
  Thrombosis Research, 1999
• Quantitative determination of a nonpeptide antithrombotic in dog plasma by microbore high-performance liquid chromatography-tandem mass spectrometry utilizing pneumatically assisted electrospray ionization
  Journal of the American Society for Mass Spectrometry, 1996
• Determination of a Depolymerized Holothurian Glycosaminoglycan in Plasma after Intravenous Administration by Postcolumn HPLC.
  CHEMICAL & PHARMACEUTICAL BULLETIN, 1995
• Unfractionated Heparin and CY 216: Pharmacokinetics and Bioavailabilities of the Antifactor Xa and IIa Effects after lntravenous and Subcutaneous Injection in the Rabbit
  Thrombosis and Haemostasis, 1989